Altimmune
ALT • NASDAQ
Altimmune is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Jerome Benedict Durso, with a market cap of $392.9M.
CEOJerome Benedict Durso
Next Earnings
Upcoming earnings announcement for Altimmune
Date
Tuesday, May 12, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.25
Revenue Estimate
$1.0K
Earnings History
Past 12 earnings reports for Altimmune
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 5, 2026 | Q4 2025 | -$0.27Est: -$0.25 | -8.0% | $26.0KEst: $560.0 | +4542.9% |  10-K |
| Nov 6, 2025 | Q3 2025 | -$0.21Est: -$0.28 | +25.0% | $5.0KEst: $560.0 | +792.9% | 10-Q |
| Aug 12, 2025 | Q2 2025 | -$0.27Est: -$0.32 | +15.6% | $5.0KEst: $560.0 | +792.9% | 10-Q |
| May 13, 2025 | Q1 2025 | -$0.26Est: -$0.35 | +25.7% | $5.0K | — | 10-Q |
| Feb 27, 2025 | Q4 2024 | -$0.33Est: -$0.34 | +2.9% | $5.0K | — | 10-K |
| Nov 12, 2024 | Q3 2024 | -$0.32Est: -$0.35 | +8.6% | $5.0K | — | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.35Est: -$0.34 | -2.9% | $5.0K | — | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.34Est: -$0.37 | +8.1% | $5.0K | — | 10-Q |
| Mar 27, 2024 | Q4 2023 | -$0.33Est: -$0.43 | +23.3% | $37.0K | — | 10-K |
| Nov 7, 2023 | Q3 2023 | -$0.39Est: -$0.42 | +7.1% | $362.0K | — | — |
| Aug 10, 2023 | Q2 2023 | -$0.32Est: -$0.46 | +30.4% | $6.0K | — | 10-Q |
| May 11, 2023 | Q1 2023 | -$0.40Est: -$0.48 | +16.7% | $21.0K | — | — |